ArticlePlastic and reconstructive surgery. Global open2024
Percutaneous Needle Fasciotomy Versus Limited Fasciectomy for Dupuytren Disease: A Linear Model Assessment of Short-term Efficacy.
Article in Plastic and reconstructive surgery. Global open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends in Treatment and Reimbursement of Dupuytren Disease.Journal of hand surgery global online · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is no consensus about the best treatment for Dupuytren contracture in the hand. In particular, whether to use a percutaneous needle fasciotomy (PCNF) in preference to a limited fasciectomy (LF). Methods: We performed a retrospective review of the outcomes of 74 joints treated with either PCNF or LF. Baseline characteristics, complications, and active extension deficit (AED) were assessed at 3 weeks and 3 months posttreatment. Reoperative procedures were analyzed to assess the effectiveness of repeated procedures. Results: Our results suggest that there is no significant difference between PCNF and LF in reducing AED at 3 weeks ( Conclusions: We believe that PCNF should be used as the primary treatment for nonrecurrent and recurrent Dupuytren contractures. More frequent use of PCNF may help to reduce waiting times for treatment and may enable better resource allocation. Further prospective studies should be carried out.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.